OTLC (Oncotelic Therapeutics) Forward Dividend Yield %: 0.00% (As of Jun. 25, 2026)


What is Oncotelic Therapeutics Forward Dividend Yield %?

Oncotelic Therapeutics OTLC -15.51% Forward Dividend Yield % is 0.00% as of Jun. 25, 2026. The stock has 4 warning signs investors should review. Among 147 Biotechnology companies, Oncotelic Therapeutics ranks worse than 680271.43% on this metric.

As of today (2026-06-25), the Forward Annual Dividend Yield of Oncotelic Therapeutics is 0.00%.

As of today (2026-06-25), the Trailing Annual Dividend Yield of Oncotelic Therapeutics is 0.00%.

OTLC's Forward Dividend Yield % is not ranked *
in the Biotechnology industry.
Industry Median: 1.51
* Ranked among companies with meaningful Forward Dividend Yield % only.

Oncotelic Therapeutics's Dividends per Share for the three months ended in Mar. 2026 was $0.00.

The growth rate is calculated with least square regression.

For more information regarding to dividend, please check our Dividend Page.

Oncotelic Therapeutics  (OTCPK:OTLC) Forward Dividend Yield % Explanation

Over the long term, the return from dividends has been a significant contributor to the total returns produced by equity securities. Studies by Elroy Dimson, Paul Marsh, and Mike Staunton of Princeton University (2002) found that a market-oriented portfolio, which included reinvested dividends, would have generated nearly 85 times the wealth generated by the same portfolio relying solely on capital gains.

Dividends may also qualify a lower tax rate for investors.

In dividends investing, Payout Ratio and Dividend Growth Rate are the two most important variables for consideration. A lower payout ratio may indicate that the company has more room to increase its dividends.

You can find the stocks that owned most by Gurus here. Or you can check out Warren Buffett's highest dividend stocks here.

Oncotelic Therapeutics Forward Dividend Yield % Related Terms

OTLC vs ALLR, MRKR, SKYE: Forward Dividend Yield % Comparison

For the Biotechnology subindustry, Oncotelic Therapeutics's Forward Dividend Yield %, along with its competitors' market caps and Forward Dividend Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Oncotelic Therapeutics Forward Dividend Yield % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Oncotelic Therapeutics's Forward Dividend Yield % distribution charts can be found below:

* The bar in red indicates where Oncotelic Therapeutics's Forward Dividend Yield % falls into.


Oncotelic Therapeutics Forward Dividend Yield % Calculation

Dividend Yield measures how much a company pays out in dividends each year relative to its share price.

What does a Forward Dividend Yield % of 0.00% mean?
Oncotelic Therapeutics (OTLC) has a Forward Dividend Yield % of 0.00% as of Jun. 25, 2026. Forward dividend yield is the ratio of company's expected dividends to the share price. View historical data on Oncotelic Therapeutics and its competitors. According to the industry distribution chart, Oncotelic Therapeutics ranks #999999 out of 147 companies in the Biotechnology industry.
Is Oncotelic Therapeutics' Forward Dividend Yield % too high?
Oncotelic Therapeutics' current Forward Dividend Yield % is 0.00%. Based on the distribution chart, Oncotelic Therapeutics ranks #999999 out of 147 companies in the Biotechnology industry, which is in the bottom quartile relative to peers.
How does Oncotelic Therapeutics' Forward Dividend Yield % compare to ALLR and MRKR?
According to the Biotechnology industry distribution chart, Oncotelic Therapeutics ranks #999999 out of 147 companies for Forward Dividend Yield %. This places Oncotelic Therapeutics in the lower half of its industry. The industry median Forward Dividend Yield % is 1.51. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Forward Dividend Yield % for a Biotechnology company?
The median Forward Dividend Yield % among Biotechnology companies is 1.51, based on 147 companies in the industry. Companies in the top quartile (top 25%) have a Forward Dividend Yield % significantly above this median, while those in the bottom quartile fall well below. However, Forward Dividend Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Forward Dividend Yield % mean?
A high Forward Dividend Yield % can signal that a stock is expensive relative to its fundamentals. Forward dividend yield is the ratio of company's expected dividends to the share price. View historical data on Oncotelic Therapeutics and its competitors. For the Biotechnology industry, the median Forward Dividend Yield % is 1.51 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Oncotelic Therapeutics's current Forward Dividend Yield % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Oncotelic Therapeutics stock overvalued right now?
Oncotelic Therapeutics (OTLC) has a current Forward Dividend Yield % of 0.00%. The current Forward Dividend Yield % is 0.00%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Forward Dividend Yield % calculated?
Forward Dividend Yield % is calculated from a company's financial statements. For Oncotelic Therapeutics (OTLC), the current Forward Dividend Yield % is 0.00% as of Jun. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Oncotelic Therapeutics Business Description

Address 29397 Agoura Road, Suite 107, Agoura Hills, CA, USA, 91301
Oncotelic Therapeutics Inc is a clinical-stage biopharmaceutical company. It focuses on developing drugs for the treatment of orphan oncology indications, developing antisense and small molecule injectable drugs for the treatment of cancer. OT-101 is its flagship immuno-oncology drug candidate. OT-101 also has activity against SARS-CoV-2. Its other products under the pipeline are Artemisinin, CA4P, AL-101, and Oxi4503.